PDS Biotechnology Announces Details of Virtual KOL Event

Stock Information for PDS Biotechnology Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PDS Biotechnology Corporation

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.